BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T041220
CREATED:20220613T094420Z
LAST-MODIFIED:20220624T095129Z
UID:34406-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Innate Killer Summit Europe
DESCRIPTION:The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T\, NK\, and Macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through innate cell targeting and engineering. \nSeize your chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Gamida Cell\, Glycostem and Bayer and gain a comprehensive overview of candidates to inform your strategic development and progress the field together with an industry brain trust. \nBridging the gap between the technicalities of early discovery through to process optimisation and leaping regulatory hurdles\, this is the must-attend meeting to accelerate safe and scalable therapies in Europe. \nTo learn more\, visit: www.innate-killer-europe.com
URL:https://www.pharmajournalist.com/event/innate-killer-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T041220
CREATED:20220620T112738Z
LAST-MODIFIED:20220620T112738Z
UID:34479-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Process Development for Cell Therapies Summit
DESCRIPTION:“The Process is the Product” – Drive Process Excellence at the Only Summit Dedicated to Process Development for Cell Therapies \n \nAs momentum continues to build for the cell therapy industry\, process development looms as a huge potential bottleneck to overcome. The inaugural Process Development for Cell Therapies Summit will give you unprecedented access to an industry melting pot of process development tools and experience to drive down cost of goods\, maximize scalability and achieve regulatory compliance. \nJoin your peers who will all be gathering to learn how to identify and plug platform gaps for automation\, global scale-out\, faster phase development\, increased affordability\, and more! \nWith 20+ case studies being presented\, you will come away with tried and tested strategies informed by industry leaders such as BMS\, Kite\, Lyell Immunopharma\, and Immatics Biotechnologies. There is no other event of this kind which is focused specifically on Process Development for Cell Therapy\, delivering case studies to provide actionable insights. \nNow is the time to gather with the industry gurus to unpick shared challenges in process development and share best practices to de-silo the industry and bring better therapies to patients faster. \nFind out more about the meeting\, who’s attending and what you could learn by downloading the latest event guide: https://ter.li/lbtpp0 \nWe look forward to welcoming you to Boston in October!
URL:https://www.pharmajournalist.com/event/process-development-for-cell-therapies-summit/
LOCATION:Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T041220
CREATED:20220622T094513Z
LAST-MODIFIED:20220622T094513Z
UID:34491-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Immunogenicity Summit
DESCRIPTION:The 3rd Annual Gene Therapy Immunogenicity Summit is industry’s definitive forum enabling you to better modulate\, measure and predict the immune response to your gene therapy candidate. \nIn the context of ever-increasing gene therapy clinical activity and uncertainty around challenges posed by immune responses to delivery\, this summit will unite large pharma and innovative biotech’s to ensure that you’re up to speed on the latest approaches to evaluate and overcome pre-existing immunity to AAV vectors\, understand how immune-modulatory strategies can help to ensure efficacy and safety and learn the reality of regulatory expectations around immunological assays. \nIncorporating insights from leading immunological\, bioanalytical\, and translational experts\, this is your opportunity to gain extensive technical information on the contrasts between immunogenicity encountered across organs and administration routes\, how models can be enhanced to enable comparative immunology between species and what the latest clinical data tells us about how to adapt existing clinical mitigation strategies to address immunogenicity. \nWith 35+ industry-based speakers covering pre-clinical and clinical immunogenicity challenges over 2 tracks and 3 packed days of content\, don’t miss your chance to join over 100+ fellow industry experts to network in person and share your research as you seek new and improved ways of predicting immunogenicity in the clinic to ultimately ensure the safety and efficacy of gene therapies. \nTo know more visit: https://ter.li/acp4lt
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-immunogenicity-summit/
LOCATION:The Colonade\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221018
DTEND;VALUE=DATE:20221021
DTSTAMP:20260516T041220
CREATED:20220714T094650Z
LAST-MODIFIED:20220714T094650Z
UID:34667-1666051200-1666310399@www.pharmajournalist.com
SUMMARY:Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:With over 100 early and managed access\, compassionate use\, and named patient programmes running across the continent\, the Operationalise: Early Access Programmes Summit Europe has been carefully curated to help you address difficulties with supply\, logistics and cost\, challenges with navigating European regulations\, and planning and running equitable\, patient-first early access programmes. \nDownload the full event guide to view the world-class speaker faculty of over 20 experienced EAP leaders\, who will be sharing their insights through best-practice case studies. \nImmerse yourself in three days of interactive sessions and discuss your peers’ approaches to involving the patient voice\, engaging different stakeholders\, planning considerations for a successful EAP and more. \nWith a specific focus on real-world case studies and practical applications\, join us to gain a greater understanding and clarity of the end-to-end management of running an early access programme in Europe.
URL:https://www.pharmajournalist.com/event/operationalise-early-access-programmes-summit-europe/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR